Q4 2024 Earnings Call Transcript March 20, 2025 Operator: Hello, and welcome to the Adaptimmune’s Q4 and Full Year 2024 ...
Adaptimmune is rolling out its T cell therapy Tecelra for synovial sarcoma, recording $1.2 million in sales since its ...
TECELRA® launch momentum accelerating – 10 patients apheresed in Q1 2025 and 3 in 2024; 20 ATCs available; all manufacturing and supply goals ...
Adrian Rawcliffe, Adaptimmune's Chief Executive Officer: "2025 is the year of commercial execution for Tecelra, as we begin to generate value from our promising sarcoma franchise. The launch is ...
FODMAP Everyday® on MSN20d
17 Rare Cancers You May Never Have Heard OfYears ago, a family member was diagnosed with an extremely rare cancer: Liposarcoma of the Spermatic Cord. Fewer than 200 cases have been reported worldwide, making this diagnosis both a blessing and ...
Were you Seen at The third annual Sarcoma Strong Gala on March 1, 2025, in Glen Sanders Mansion in Scotia? Were you Seen at The third annual Sarcoma Strong Gala on March 1, 2025, in Glen Sanders ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback